News & Updates

Show Multimedia Only
Finerenone protects kidneys in patients with T1D + CKD Finerenone protects kidneys in patients with T1D + CKD

Finerenone protects kidneys in patients with T1D + CKD

09 Apr 2026 byChristina Lau

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

09 Apr 2026